

Simone Ferrero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7042454/publications.pdf>

Version: 2024-02-01

107
papers

3,144
citations

218381

26
h-index

168136

53
g-index

114
all docs

114
docs citations

114
times ranked

4311
citing authors

#	ARTICLE	IF	CITATIONS
1	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.	0.6	345
2	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014, 28, 1299-1307.	3.3	257
3	Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2077-2084.	0.8	246
4	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018, 132, 2115-2124.	0.6	232
5	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012, 119, 2066-2073.	0.6	217
6	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	1.2	115
7	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
8	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1062-1072.	3.3	97
9	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
10	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015, 29, 689-695.	3.3	75
11	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
12	Highly sensitive <i>MYD88</i> ^{L265P} mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, 1029-1037.	1.7	61
13	Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. <i>Leukemia</i> , 2012, 26, 1081-1090.	3.3	59
14	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	3.3	56
15	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642.	0.6	55
16	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	0.6	53
17	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019, 185, 940-944.	1.2	49
18	How to manage mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 2117-2130.	3.3	44

#	ARTICLE	IF	CITATIONS
19	Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. <i>Hematological Oncology</i> , 2011, 29, 167-176.	0.8	36
20	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. <i>HemaSphere</i> , 2020, 4, e347.	1.2	36
21	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
22	Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112.	1.9	33
23	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 1211-1214.	3.3	33
24	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017, 8, 5924-5935.	0.8	33
25	New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?. <i>Clinical Cancer Research</i> , 2014, 20, 5194-5206.	3.2	31
26	The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?. <i>Haematologica</i> , 2016, 101, 104-114.	1.7	31
27	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
28	A novel phage display based platform for exosome diversity characterization. <i>Nanoscale</i> , 2022, 14, 2998-3003.	2.8	27
29	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	0.8	25
30	Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. <i>Methods in Molecular Biology</i> , 2018, 1768, 229-256.	0.4	24
31	New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. <i>Journal of Clinical Medicine</i> , 2018, 7, 288.	1.0	24
32	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
33	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017, 102, e203-e206.	1.7	21
34	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	1.7	21
35	Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?. <i>Haematologica</i> , 2017, 102, 1133-1136.	1.7	20
36	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. <i>Annals of Hematology</i> , 2013, 92, 1503-1511.	0.8	19

#	ARTICLE	IF	CITATIONS
37	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. Hematological Oncology, 2019, 37, 153-154.	0.8	19
38	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. Biology of Blood and Marrow Transplantation, 2018, 24, 1814-1822.	2.0	18
39	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American Journal of Hematology, 2020, 95, 1553-1561.	2.0	18
40	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Reports Medicine, 2020, 1, 100158.	3.3	18
41	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. Cancers, 2021, 13, 291.	1.7	17
42	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. Blood, 2020, 136, 29-30.	0.6	16
43	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853.	1.7	14
44	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. Journal of Geriatric Oncology, 2020, 11, 37-40.	0.5	14
45	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. Diagnostics, 2021, 11, 779.	1.3	14
46	Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood, 2022, 140, 1378-1389.	0.6	14
47	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. Hematological Oncology, 2019, 37, 368-374.	0.8	13
48	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	0.8	12
49	Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. Leukemia, 2016, 30, 984-987.	3.3	11
50	HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. BMC Bioinformatics, 2017, 18, 516.	1.2	10
51	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. HemaSphere, 2020, 4, e302.	1.2	10
52	Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.. Blood, 2009, 114, 99-99.	0.6	10
53	Ficoll-paque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. International Journal of Laboratory Hematology, 2018, 40, 201-208.	0.7	8
54	Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification. Blood, 2018, 132, 920-920.	0.6	8

#	ARTICLE	IF	CITATIONS
55	How to treat old MCL patients: one size fits it all?. Blood, 2014, 124, 1207-1208.	0.6	7
56	FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematological Oncology, 2019, 37, 224-225.	0.8	7
57	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. JCO Clinical Cancer Informatics, 2019, 3, 1-15.	1.0	7
58	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. American Journal of Hematology, 2020, 95, 1473-1478.	2.0	7
59	Data quality improvement of a multicenter clinical trial dataset. , 2017, 2017, 1190-1193.		6
60	Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. Current Treatment Options in Oncology, 2018, 19, 71.	1.3	6
61	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. American Journal of Hematology, 2020, 95, 1030-1037.	2.0	6
62	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. Journal of Personalized Medicine, 2021, 11, 249.	1.1	6
63	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. Hematological Oncology, 2021, 39, 293-303.	0.8	6
64	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. Cancers, 2022, 14, 188.	1.7	6
65	The current therapeutic scenario for relapsed mantle cell lymphoma. Current Opinion in Oncology, 2013, 25, 452-462.	1.1	5
66	Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. Haematologica, 2015, 100, 706-708.	1.7	5
67	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. Hematological Oncology, 2018, 36, 689-692.	0.8	5
68	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. Haematologica, 2019, 104, e410-e414.	1.7	5
69	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Annals of Hematology, 2020, 99, 2197-2199.	0.8	5
70	Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. British Journal of Haematology, 2021, 194, 378-381.	1.2	5
71	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. Diagnostics, 2022, 12, 969.	1.3	5
72	Novel CALR somatic mutations in essential thrombocythaemia. British Journal of Haematology, 2016, 173, 797-801.	1.2	4

#	ARTICLE	IF	CITATIONS
73	THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 248-250.	0.8	4
74	MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305.	1.2	4
75	A brief rituximab, bendamustine, mitoxantrone (R ² BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
76	COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. <i>HemaSphere</i> , 2021, 5, e592.	1.2	4
77	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
78	OUTCOMES IN FIRST RELAPSED/REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. <i>Hematological Oncology</i> , 2019, 37, 46-47.	0.8	3
79	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 698-704.	0.8	3
80	Droplet Digital PCR Assay for <i>MYD88^{L265P}</i> : Clinical Applications in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2020, 4, e324.	1.2	3
81	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
82	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009, 114, 960-960.	0.6	3
83	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
84	KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL. <i>Hematological Oncology</i> , 2017, 35, 94-95.	0.8	2
85	Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 105.	0.4	2
86	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. <i>Blood</i> , 2010, 116, 3375-3375.	0.6	2
87	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. <i>Blood Advances</i> , 2021, 5, 3188-3198.	2.5	2
88	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 48-48.	0.6	2
89	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.	0.6	2
90	NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY. <i>Hematological Oncology</i> , 2017, 35, 151-151.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. British Journal of Haematology, 2018, 181, 693-695.	1.2	1
92	PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK. HemaSphere, 2019, 3, 599.	1.2	1
93	ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. Blood, 2019, 134, 1565-1565.	0.6	1
94	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). Blood, 2012, 120, 788-788.	0.6	1
95	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. Blood, 2015, 126, 1411-1411.	0.6	1
96	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. Blood, 2010, 116, 1784-1784.	0.6	1
97	Letermovir Prophylaxis Versus Pre-Emptive Therapy for Cytomegalovirus after Hematopoietic Stem-Cell Transplantation. Blood, 2021, 138, 4861-4861.	0.6	1
98	HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. Journal of Personalized Medicine, 2022, 12, 285.	1.1	1
99	OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY LINFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI. Hematological Oncology, 2017, 35, 183-184.	0.8	0
100	MANTLE CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematological Oncology, 2017, 35, 202-203.	0.8	0
101	Minimal residual disease by next-generation sequencing in mantle cell lymphoma: The bioinformatics tool <sc>HashClone</sc>. Hematological Oncology, 2017, 35, 299-300.	0.8	0
102	ParallelHashClone: A Parallel Implementation of HashClone Suite for Clonality Assessment from NGS Data. , 2018, , .		0
103	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. HemaSphere, 2021, 5, e639.	1.2	0
104	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. Blood, 2010, 116, 2951-2951.	0.6	0
105	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. Blood, 2012, 120, 4204-4204.	0.6	0
106	The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. , 2015, , 143-168.		0
107	Influenza Vaccination in Asplenia: Improving Quality of Care in Time of Coronavirus. Blood, 2020, 136, 39-40.	0.6	0